SAREPTA THERAPEUTICS, INC. Restructuring and Related Cost, Accelerated Depreciation
SAREPTA THERAPEUTICS, INC. (SRPT) reported Restructuring and Related Cost, Accelerated Depreciation of $800.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveAcceleratedDepreciation · last filed 2017-02-28
- SAREPTA THERAPEUTICS, INC. restructuring and related cost, accelerated depreciation for fiscal 2016 was $800.00K.
| Period end | Restructuring and Related Cost, Accelerated Depreciation 12 month |
|---|---|
| 2016-12-31 | $800.00K 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |